Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Reportedly, the child experienced mild symptoms and has received flu antivirals.

A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.

Currently, there are no treatments for the serious, rare pediatric disease.

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

Once-daily icotrokinra versus placebo demonstrated clinically significant skin clearance in those with moderate-to-severe plaque psoriasis.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

Results demonstrated that daily oral infigratinib treatment led to increases in annualized height velocity and improvement in body proportionality.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

With this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.

With the decision, Kebilidi becomes the first FDA-approved gene therapy for AADC deficiency, and is indicated for adult and pediatric patients.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.

The primary endpoint of the study was survival free of BPD at 36 weeks' postmenstrual age.

A key update includes providing CPR with rescue breaths and chest compressions to all persons in cardiac arrest after water removal.

Data stems from the first 4 patients dosed in a low-dose cohort of an ongoing phase 1/2 open-label trial.

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.

At any point in the study, adolescents who used cannabis reported a greater number of psychosis spectrum symptoms.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

A study of over 1 million births in Quebec reveals that pregnant women with hidradenitis suppurativa face increased risks of pregnancy complications and long-term health issues for both themselves and their offspring.

The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

The federal agency has not raised any concerns regarding safety and efficacy of tapinarof cream, 1%.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

Application acceptance was based on positive results with monthly and bi-monthly dosing data from a phase 3 trial.